1. Omar Ishrak - Medtronic

Omar Ishrak

2014 pay: $12.1 million
2015 pay: $39.4 million

Medtronic ($MDT) CEO Omar Ishrak didn’t waste any time in 2015 after the company’s deal with Covidien closed. The med tech helmsman steered the company toward growth and promised cost savings from the acquisition.

The company is on track to meet its goal of saving $300 million to $350 million from acquiring Covidien, Ishrak said late last year on a Q1 2016 earnings call. Medtronic has already shuttered redundant facilities, and now it’s looking for opportunities for synergy, Ishrak said.

A particular area of interest is peripheral vascular. Medtronic picked up Covidien’s drug-coated balloons through the acquisition, and the company plans to leverage the company’s neurovascular unit to bolster its restorative therapies group, Ishrak said last year.

Ishrak also led Medtronic through expansion on the R&D front. In 2015, the company got FDA approval for its second-generation TAVR, giving it ammo against rival Edwards Lifesciences ($EW). Medtronic is also working on robotic surgery devices to compete in a fast-growing market.

Even though Medtronic has stayed quiet on the M&A front lately, more deals could be on the horizon. “We remain disciplined when evaluating potential M&A opportunities,” Ishrak said in September. “Any investment we must make, any investment we make must be aligned with and ultimately strengthen one or more of our three growth strategies while at the same time offer high return metrics and minimize near-term shareholders dilution," he said.

Ishrak’s $39.4 million pay in 2015 included $1.5 million in base salary, $3.5 million in stock awards, $3 million in options, $5.6 million in non-equity incentives and $25.5 million in “other compensation.”

- here’s Medtronic’s proxy statement

For more:
Medtronic's Ishrak says Covidien integration on track to meet cost savings of up to $350M
Robotic surgery to see new entrants Medtronic and J&J/Google, but Intuitive still miles ahead
Medtronic strikes back with FDA approval of its second-gen TAVR
Launches lead the way as Medtronic beats the Street

1. Omar Ishrak - Medtronic

Suggested Articles

The FDA has cleared Drawbridge Health’s blood collection device designed to help monitor long-term blood sugar levels in people with diabetes.

FierceMedTech Fierce 15 winner 10x Genomics announced its plans for a $100 million IPO, on the Nasdaq using the symbol TXG.

Belgian devicemaker Miracor Medical received a breakthrough designation from the FDA for its treatment designed to limit the damage of a heart attack.